N

NuVasive Inc
F:NK8

Watchlist Manager
NuVasive Inc
F:NK8
Watchlist
Price: 36.8 EUR Market Closed
Market Cap: €1.9B

NuVasive Inc
Investor Relations

In the ever-evolving world of healthcare innovation, NuVasive Inc. stands as a noteworthy beacon in the field of spinal surgery technology. Founded in 1997 and based in San Diego, California, the company has carved a niche for itself with its minimally invasive surgical procedures designed to transform spinal care. The cornerstone of its success lies in its proprietary Maximum Access Surgery (MAS) platform, which reduces operating time and recovery periods for patients undergoing spinal procedures. By integrating its cutting-edge surgical solutions with advanced neuromonitoring technology and a comprehensive suite of procedural systems, NuVasive aids surgeons in executing complex operations with precision and efficiency. This unique amalgamation of technology and medical expertise not only enhances surgical outcomes but also has cemented NuVasive’s reputation as a leader in less-invasive spinal surgery.

Financially, NuVasive harnesses an effective business model that generates revenue through the sale of its specialized surgical equipment, including implants and biologics, as well as through service offerings like its intraoperative monitoring services. The company's revenue streams are largely driven by product sales directly to hospitals and surgical centers, where innovative tools and technologies are in high demand. As healthcare facilities increasingly seek advanced methods to improve patient outcomes and operating efficiencies, NuVasive finds itself at the forefront of this demand, continuously expanding its product portfolio and global reach. By investing heavily in research and development, the company ensures its products stay at the cutting edge of medical technology, providing not just immediate financial growth, but also a long-term strategic advantage in the global market for spinal surgery solutions.

Show more
Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
Last Earnings Call
Fiscal Period
Q2 2023
Call Date
Aug 2, 2023
Q2 2023 Earnings Call
No Analysis Available

This earnings call has not been analyzed yet.

If you’d like us to analyze this earnings call, click the "Request Earnings Call Analysis" button below.

Request Earnings Call Analysis
Earnings Call Recording
Other Earnings Calls

Management

Mr. J. Christopher Barry
CEO & Director
No Bio Available
Mr. Matthew K. Harbaugh
Exec. VP & CFO
No Bio Available
Mr. Dale A. Wolf
Sr. VP of Global Operations
No Bio Available
Mr. Nathaniel B. Sisitsky Esq.
Sr. VP, Gen. Counsel & Corp. Sec.
No Bio Available
Mr. Marc Rosenbaum
VP, Corp. Controller & Chief Accounting Officer
No Bio Available
Mr. Ryan Donahoe
Sr. VP & Chief Technology Officer
No Bio Available
Mr. Johnson Lai
Chief Information Officer
No Bio Available
Ms. Juliet C. Cunningham
VP of Investor Relations
No Bio Available
Mr. Michael Farrington
Sr. VP of People & Culture
No Bio Available
Mr. Sean Freeman
Sr. VP of Strategy & Corp. Devel.
No Bio Available

Contacts

Address
CALIFORNIA
San Diego
7475 Lusk Blvd
Contacts
+18589091800.0
www.nuvasive.com